Congenital Spinal Malformation and Stroke: Aneurysmal Dilatations and Bilateral Rotational Vertebral Artery Occlusion.
de la Riva P, Martínez-Zabaleta MT, Pardo E, Samprón N, Mondragón-Rezola E, Arruti González M, Larrea JÁ, Martí-Massó JF.
Journal Of Stroke & Cerebrovascular Diseases. 2016; 25: 23-24. FI: 1,517 (Q4).
Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting.
Fernandez O, Rodriguez-Antiguedad A, Olascoaga J, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Saiz A, Calles-Hernandez MC, Izquierdo G, Villar LM, Oliva-Nacarino P, Arnal-Garcia C, Comabella M, Brieva L, Arroyo R, Montalban X.
Revista De Neurologia. 2016; 62: 559-569. FI: 0,743 (Q4).
Respuesta al tratamiento con interferon beta en pacientes con esclerosis multiple. Validacion del Rio Score.
Rio J, Rovira A, Blanco Y, Sainz A, Perkal H, Robles R, Ramio-Torrenta L, Diaz RM, Arroyo R, Urbaneja P, Fernandez O, Garcia-Merino JA, Reyes MP, Oreja-Guevara C, Prieto JM, Izquierdo G, Olascoaga J, Alvarez-Cermeno JC, Simon E, Pujal B, Comabella M, Montalban X.
Revista De Neurologia. 2016; 63: 145-150. FI: 0,743 (Q4).
Fingolimod: efectividad y seguridad en la practica clinica habitual. Estudio observacional, retrospectivo y multicentrico en Navarra, Gipuzkoa y La Rioja.
Ayuso T, Marzo-Sola ME, Castillo-Trivino T, Soriano G, Otano MA, Lopez MA, Croitoru IM, Olascoaga J.
Revista De Neurologia. 2016; 63: -. FI: 0,743 (Q4).
Luminal B breast cancer subtype displays a dicotomic epigenetic pattern.
Bediaga NG, Beristain E, Calvo B, Viguri MA, Gutierrez-Corres B, Rezola R, Ruiz-Diaz I, Guerra I, de Pancorbo MM.
Springerplus. 2016; 5: 623-623. FI: 1,13 (Q2).
Inflammaging and Frailty Status Do Not Result in an Increased Extracellular Vesicle Concentration in Circulation.
Alberro A, Sáenz-Cuesta M, Muñoz-Culla M, Mateo-Abad M, Gonzalez E, Carrasco-Garcia E, Araúzo-Bravo MJ, Matheu A, Vergara I, Otaegui D.
International Journal Of Molecular Sciences. 2016; 17: -. FI: 3,226 (Q2).
scmamp: Statistical Comparison of Multiple Algorithms in Multiple Problems.
Calvo B, Santafe G.
R J. 2016; 8: 248-256. FI: 1,075 (Q2).
Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective.
Jansen A, van Deuren M, Miller J, Litzman J, de Gracia J, Sáenz-Cuesta M, Szaflarska A, Martelius T, Takiguchi Y, Patel S, Misbah S, Simon A, Good syndrome Study Group.
Clinical Immunology. 2016; 171: 12-17. FI: 3,99 (Q2).
Ferritin-mediated siRNA delivery and gene silencing in human tumor and primary cells.
Li L, Muñoz-Culla M, Carmona U, Lopez MP, Yang F, Trigueros C, Otaegui D, Zhang L, Knez M.
Biomaterials. 2016; 98: 143-151. FI: 8,402 (Q1).
Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand'Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M, MSBase Study Group.
Annals Of Neurology. 2016; 80: 89-100. FI: 9,89 (Q1).
DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson’s disease.
Bergareche A, Rodríguez-Oroz MC, Estanga A, Gorostidi A, López de Munain A, Castillo-Triviño T, Ruiz-Martínez J, Mondragón E, Gaig C, Lomeña F, Sarasqueta C, Tolosa E, Martí-Massó JF.
Movement Disorders. 2016; 31: 335-343. FI: 7,072 (Q1).
SncRNA (microRNA &snoRNA) opposite expression pattern found in multiple sclerosis relapse and remission is sex dependent.
Muñoz-Culla M, Irizar H, Sáenz-Cuesta M, Castillo-Triviño T, Osorio-Querejeta I, Sepúlveda L, López de Munain A, Olascoaga J, Otaegui D.
Scientific Reports. 2016; 6: 20126-20126. FI: 4,259 (Q1).
PerMallows: An R Package for Mallows and Generalized Mallows Models.
Irurozki, E, Calvo B, Lozano JA.
J Stat Softw. 2016; 71: 1-30. FI: 9,436 (Q1).
Defining secondary progressive multiple sclerosis.
Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T, MSBase Study Group.
Brain. 2016; 139: 2395-2405. FI: 10,292 (Q1).
